Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

AbbVie stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm's fourth-quarter revenue exceeded ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

In last week’s Sunday Digest, I (Tom Yeung) wrote how cyclical companies are often incredible investments. Firms like copper ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

Humira's market leadership came under threat in 2024, reaching 77% in May as large pharmacy benefit managers such as CVS Health (CVS) removed the branded version from major drug formularies.

Seigerman anticipates that the decline in Humira sales in 2025 will be less ... are likely to contribute to significant revenue growth for the drug. The company maintains strong financial health ...

From the biologics’ first US Food and Drug Administration (FDA) approval in 2002 until 2023, Humira generated $187bn in revenues for AbbVie. Speaking at the JP Morgan Healthcare Conference 2025 ...

It’s important to take the clonidine dosage your doctor prescribes. Clonidine comes as an IR oral tablet. With IR medications, the active drug is released into your bloodstream right away after ...

charts in the U.K. this week, but oddly, there's no crossover. LOS ANGELES, CALIFORNIA - NOVEMBER 01: Harry Styles attends the Los Angeles Premiere of "My Policeman" at Regency Bruin Theatre on ...

Elvis Presley earns his second No. 1 on Billboard's Top Rock Albums chart as The Classic Christmas ... [+] Album finally hits the top spot years after its release. BURBANK, CA - JUNE 27 ...

Over the last five years, the industry has traded as high as 20.70X, as low as 13.31X and at a median of 15.31X, as the chart below shows ... s blockbuster drug, Humira, are declining due to ...